Keros Therapeutics Inc
NASDAQ:KROS
Keros Therapeutics Inc
Revenue
Keros Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Keros Therapeutics Inc
NASDAQ:KROS
|
Revenue
$3.6m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Keros Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Keros Therapeutics Inc
Breakdown by Segments
Keros Therapeutics Inc
|
Total Revenue:
3.6m
USD
|
|
Reportable Segment:
3.6m
USD
|
|
License Revenue:
3m
USD
|
|
Service:
3m
USD
|
Keros Therapeutics Inc
Glance View
In the heart of the biotechnology sector lies Keros Therapeutics Inc., a company heralded for its innovative approach in addressing unfulfilled needs within hematological and musculoskeletal disorders. Established with a keen focus on advancing therapies derived from the Transforming Growth Factor-Beta (TGF-β) family of proteins, Keros aims to reshape the treatment landscape of complex diseases. Through a scientific approach anchored in proprietary technology, Keros navigates the intricate pathways of cellular growth and differentiation, thereby developing therapeutics with the potential to significantly improve patients' quality of life. Their pipeline, headlined by lead product candidates like KER-050 and KER-047, targets conditions such as myelodysplastic syndromes and fibrodysplasia ossificans progressiva, conditions that have long posed challenges to traditional medical interventions. Keros Therapeutics generates revenue primarily through the development and potential commercialization of its targeted therapies. By advancing their candidates through various clinical trial phases, Keros seeks to unlock significant market opportunities in sectors characterized by high demand and limited treatment options. Partnerships and strategic collaborations further bolster their financial backbone, as these relationships often bring in milestone payments and future royalty arrangements. The company’s model is one of strategic innovation—leveraging cutting-edge science to address critical health issues while carving out a competitive niche in the biotechnology market. This robust approach not only fuels potential breakthroughs but also charts a sustainable path toward profitability in an industry where the aspirations to alleviate complex medical conditions align seamlessly with business growth potentials.
See Also
What is Keros Therapeutics Inc's Revenue?
Revenue
3.6m
USD
Based on the financial report for Dec 31, 2024, Keros Therapeutics Inc's Revenue amounts to 3.6m USD.
What is Keros Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-19%
Over the last year, the Revenue growth was 2 251%. The average annual Revenue growth rates for Keros Therapeutics Inc have been -44% over the past three years , -19% over the past five years .
You don't have any saved screeners yet